GlassScriptPhysician profile
Paul A Berkowitz
NPI 1053371286
$1,065.83
in general payments reported to CMS, 2019-2025
17 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $96.07 · 2021: $175 · 2022: $97.13 · 2023: $43.31 · 2024: $204 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436 · Education: $36.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.55 |
| Education | $36.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185.08 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $116.99 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $111.28 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $103.25 | 2024-2025 | Filspari |
| Glaxosmithkline, LLC. | $84.79 | 2021-2025 | Benlysta |
| Fresenius USA Marketing, INC. | $84.07 | 2019 | |
| Akebia Therapeutics INC | $67.20 | 2024-2025 | Vafseo, Auryxia |
| Amgen INC. | $49.26 | 2019-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.73 | 2025 | Jardiance |
| Horizon Therapeutics Plc | $41.19 | 2022-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $40.41 | 2020 | |
| Aurinia Pharma U.S., INC. | $30.95 | 2022 | |
| Mallinckrodt Enterprises LLC | $28.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.53 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.28 | 2024 | Ultomiris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.16 | 2021 | |
| Amarin Pharma, INC. | $16.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.